FdaApplication
BLA 103606
Identifiers
- fda_app_no: BLA103606
Properties
| Property | Value |
|---|---|
| applicant_name | Merck Sharp & Dohme LLC |
| application_type | BLA |
| approval_date | 1996-03-29 |
Revenue by product
VAQTA
| Period | Revenue |
|---|---|
| Q4 2023 | $29.0M |
| Q3 2023 | $69.0M |
| Q2 2023 | $42.0M |
| Q1 2023 | $40.0M |
| Q4 2022 | $39.0M |
| Q3 2022 | $64.0M |
| Q2 2022 | $35.0M |
| Q1 2022 | $36.0M |
| Q4 2021 | $41.0M |
| Q3 2021 | $48.0M |
| Q2 2021 | $56.0M |
| Q1 2021 | $34.0M |
| Q4 2020 | $31.0M |
| Q3 2020 | $51.0M |
| Q2 2020 | $28.0M |
| Q1 2020 | $60.0M |
| Q4 2019 | $71.0M |
| Q3 2019 | $62.0M |
| Q2 2019 | $58.0M |
| Q1 2019 | $47.0M |
| Q4 2018 | $72.0M |
| Q3 2018 | $66.0M |
| Q2 2018 | $65.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VAQTA | — | 50U/ML | Injection |
| VAQTA | — | 50U/ML | Injection |
| VAQTA | — | 25U/.5ML | Injection |
| VAQTA | — | 25U/.5ML | Injection |
4 products